

# Global Central Nervous System Therapeutic Market : Trends, Opportunities and Forecasts (2019-2024)

- **By Disease**- Cancer, Neurovascular, Degenerative disorder, Mental Health, Trauma and Infection
- **By Region** - North America, Europe, Asia Pacific and ROW.
- **By Country** - U.S, Canada, U.K, Germany, Japan, China, India and Brazil.



# Scope of the Report – Global Central Nervous System Therapeutic Market



			2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	
Global	Market (By Value)													
	By Disease, By Value	Cancer	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
		Neurovascular	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
		Degenerative disorder	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
		Mental Health	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
		Trauma	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
		Infection	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Regional	By Disease, By Value	Cancer	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	
		Neurovascular	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	
		Degenerative disorder	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	
		Mental Health	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	
		Trauma	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	
		Infection	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	
Company Analysis	Biogen, Pfizer, Teva Pharmaceuticals, Novartis, Johnson & Johnson, Shire, Merck & Co., AstraZeneca, Otsuka Pharmaceutical, Eli Lilly													
Regional Analysis	North America, Europe, APAC and ROW													
Country Analysis	U.S, Canada, U.K., Germany, Japan, China, India, Brazil													

# Table of Content

S.No	Particulars	Page No.
1.	Research Methodology	24
2.	Executive Summary	25
3.	Strategic Recommendation	26
3.1	Lucrative scope in neurodegenerative therapeutic market	27
3.2	APAC region to witness augmented growth in the forecast period	28
4.	Central Nervous System Therapeutic Market: Product Outlook	29
5.	Global Central Nervous System Therapeutic Market : Growth and Forecast	37
5.1	By Value (2014-2018)	38
5.2	By Value (2019-2024)	39
6.	Global Central Nervous System Therapeutic Market : Segmental Analysis	50

# Table of Content

S.No	Particulars	Page No.
6.1	Global Central Nervous System Therapeutic Market Size, By Type: Breakdown (%)	51
6.1.1	Global Central Nervous System Therapeutic Market Size, By Type, 2018 (%)	52
6.1.2	Global Central Nervous System Therapeutic Market Size, By Type, 2024 (%)	53
6.2	Global Cancer Market, By Value (2014-2024)	54
6.3	Global Neurovascular Market, By Value (2014-2024)	55
6.4	Global Neurodegenerative disorder Market, By Value (2014-2024)	56
6.5	Global Mental Health Market, By Value (2014-2024)	59
6.6	Global Trauma Market, By Value(2014-2024)	60
6.7	Global Infection Market, By Value (2014-2024)	63
7.	Global Central Nervous System Therapeutic Market : Regional Analysis	64

# Table of Content

S.No	Particulars	Page No.
7.1	Global Central Nervous System Therapeutic Market Size, By Region : Breakdown (%)	30
7.1.1	Global Central Nervous System Therapeutic Market Size, By Region, 2018 (%)	66
7.1.2	Global Central Nervous System Therapeutic Market Size, By Region, 2024 (%)	67
7.2	North America Central Nervous System Therapeutic Market: Growth and Forecast	68
7.2.1	By Value (2014-2018)	69
7.2.2	By Value (2019-2024)	70
7.2.3	By Type, By Value (2014-2018)	76
7.2.4	By Type, By Value (2019-2024)	76
7.3	North America Central Nervous System Therapeutic Market: Country Analysis (U.S and Canada)	78
7.3.1	U.S Central Nervous System Therapeutic Market, By Value (2014-2024)	79

# Table of Content

	Particulars	Page No.
7.3.2	Canada Central Nervous System Therapeutic Market, By Value (2014-2024)	80
7.4	Europe Central Nervous System Therapeutic Market: Growth and Forecast	86
7.4.1	By Value (2014-2018)	87
7.4.2	By Value (2019-2024)	88
7.4.3	By Type, By Value (2014-2018)	104
7.4.4	By Type, By Value (2019-2024)	105
7.5	Europe Central Nervous System Therapeutic Market: Country Analysis (U.K and Germany)	106
7.5.1	U.K Central Nervous System Therapeutic Market, By Value (2014-2024)	107
7.5.2	Germany Central Nervous System Therapeutic Market, By Value (2014-2024)	113
7.6	APAC Central Nervous System Therapeutic Market: Growth and Forecast	118

# Table of Content

	Particulars	Page No.
7.6.1	By Value (2014-2018)	119
7.6.2	By Value (2019-2024)	120
7.6.3	By Type, By Value (2014-2018)	126
7.6.4	By Type, By Value (2019-2024)	127
7.7	APAC Central Nervous System Therapeutic Market: Country Analysis (Japan, India and China)	128
7.7.1	China Central Nervous System Therapeutic Market, By Value (2014-2024)	129
7.7.2	Japan Central Nervous System Therapeutic Market, By Value (2014-2024)	135
7.7.3	India Central Nervous System Therapeutic Market, By Value (2014-2024)	141
7.8	ROW Central Nervous System Therapeutic Market: Growth and Forecast	149
7.8.1	By Value (2014-2018)	150

# Table of Content

	Particulars	Page No.
7.8.2	By Value (2019-2024)	151
7.8.3	By Type, By Value (2014-2018)	157
7.8.4	By Type, By Value (2019-2024)	158
7.9	ROW Central Nervous System Therapeutic Market: Country Analysis (Brazil)	159
7.9.1	Brazil Central Nervous System Therapeutic Market, By Value (2014-2024)	160
8.	Global Central Nervous System Therapeutic Market Dynamics	165
8.1	Global Central Nervous System Therapeutic Market Drivers	166
8.2	Global Central Nervous System Therapeutic Market Restraints	172
9.	Global Central Nervous System Therapeutic Market Trends	175
10.	Porter Five Force Analysis	178



# Table of Content

S.No	Particulars	Page No.
11.	SWOT Analysis	180
12.	Supply Chain Analysis	182
13.	Policy and Regulatory Landscape	184
14.	Company Profiling	193
14.1	Biogen	194
14.2	Pfizer	196
14.3	Teva Pharmaceuticals	198
14.4	Novartis	200
14.5	Johnson & Johnson	202
14.6	Shire	204

# Table of Content

S.No	Particulars	Page No.
14.7	Merck & Co.	206
14.8	AstraZeneca	208
14.9	Otsuka Pharmaceutical	210
14.10	Eli Lilly	212
15.	About Us	214

# List of Figures

Figure No.	Figure Title	Page No.
Figure 1:	Flowchart of Nervous System	30
Figure 2:	Tumor Grade Descriptions	35
Figure 3:	Overview of major subcategories of central nervous system disorders	36
Figure 4:	Global Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)	38
Figure 5:	Global Central Nervous System Therapeutic Market Size, By Value, Forecast, 2019-2024 (USD Billion)	39
Figure 6:	Global Overweight Population (Age above 18), 2015-2018 (% of total)	40
Figure 7:	Global Overweight Population (Age above 18), By Sex, 2018 (% of total)	40
Figure 8:	Smoking Prevalence Among Adults, By Gender, 2015	41
Figure 9:	Cigarette Sales Share, By Region, 2017 (% of total)	41
Figure 10:	Distributions of persons aged 60 years or above by region in millions, 2015 and 2030F	42
Figure 11:	Global Aged Population (Above 65), 2014-2018 (% of total)	43
Figure 12:	Regions with dedicated policies for neurological disorders, In 2017, ( In %)	44
Figure 13:	Countries with dedicated policies for neurological disorders, Based on income group, In 2017, In %	44
Figure 14:	Healthcare Expenditure (Share of GDP), By Selected Country, 2014-2018 (In %)	46
Figure 15:	Expected Global Medical Spending in 2020, By Product Type, (% of Total)	46

# List of Figures

Figure No.	Figure Title	Page No.
Figure 16:	Expected Global Medical Spending in 2020, By Region, (% of Total)	46
Figure 17:	Most frequent neurological diseases reported in primary care, In 2017	47
Figure 18:	Most frequent neurological diseases reported in primary care, In 2017	48
Figure 19:	Regional Expected Healthcare Industry Growth Rate By Year 2020	48
Figure 20:	GDP Per Capita PPP, By Region, 2018 (in Thousand USD)	49
Figure 21:	Projected global population aged 60 years & above (In Billions)	49
Figure 22:	Global Central Nervous System Therapeutic Market Size, By Type, 2017 (In %)	52
Figure 23:	Global Central Nervous System Therapeutic Market Size, By Type, 2023 (In %)	53
Figure 24:	Global Cancer Market, By Value, 2014-2018 (USD Billion)	54
Figure 25:	Global Cancer Market, By Value, Forecast, 2019-2024(USD Billion)	54
Figure 26:	Global Neurovascular Market, By Value, 2014-2018 (USD Billion)	55
Figure 27:	Global Neurovascular Market, By Value, Forecast, 2019-2024(USD Billion)	55
Figure 28:	Global Neurodegenerative Market, By Value, 2014-2018 (USD Billion)	56
Figure 29:	Global Neurodegenerative Market, By Value, Forecast, 2019-2024(USD Billion)	56
Figure 30:	Global Neurodegenerative Therapeutic Market Size, By Value, 2018 (%)	57

# List of Figures

Figure No.	Figure Title	Page No.
Figure 31:	Global Neurodegenerative Therapeutic Market Size, By Value, 2024 (%)	58
Figure 32:	Global Mental Health Market, By Value, 2014-2018 (USD Billion)	59
Figure 33:	Global Mental Health Market, By Value, Forecast, 2019-2024(USD Billion)	59
Figure 34:	Global Trauma Market, By Value, 2014-2018 (USD Billion)	60
Figure 35:	Global Trauma Market, By Value, Forecast, 2019-2024(USD Billion)	60
Figure 36:	Global TraumaTherapeutic Market Size, By Value, 2018 (%)	61
Figure 37:	Global TraumaTherapeutic Market Size, By Value, 2024 (%)	62
Figure 38:	Global Brain Infection Market, By Value, 2014-2018 (USD Billion)	63
Figure 39:	Global Brain Infection Market, By Value, Forecast, 2019-2024(USD Billion)	63
Figure 40:	Global Healthcare Landscape, By Select Region	65
Figure 41:	Global Central Nervous System Therapeutic Market Size, By Region, 2018 (%)	66
Figure 42:	Global Central Nervous System Therapeutic Market Size, By Region, 2024 (%)	67
Figure 43:	North America Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)	69
Figure 44:	North America Central Nervous System Therapeutic Market Size, By Value, Forecast, 2019-2024 (USD Billion)	70
Figure 45:	North America Population Ages 65 and above, 2012-2017 (% of Total)	72

# List of Figures

Figure No.	Figure Title	Page No.
Figure 46:	North America Healthcare Cost Per Capita, 2017 (USD)	72
Figure 47:	Most frequent neurological diseases reported in primary care, In North America, 2017	73
Figure 48:	North America GDP, 2012-2017 (USD Trillion)	74
Figure 49:	North America GDP per capita, current prices, 2013-2023F (In USD)	74
Figure 50:	North America Central Nervous System Therapeutic Market: By Type, By Value, 2014-2018 (USD Billion)	76
Figure 51:	North America Central Nervous System Therapeutic Market: By Type, By Value, 2019E-2024F (USD Billion)	77
Figure 52:	U.S. Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)	79
Figure 53:	U.S. Central Nervous System Therapeutic Market Size, By Value, 2019-2024 (USD Billion)	80
Figure 54:	Most costly neurological disorders in United States, In 2017	83
Figure 55:	U.S., Per Capita Expenditure on Healthcare, 2012-2018 (In USD)	83
Figure 56:	Proportion of people with Alzheimer disease, In United States, In 2017	84
Figure 57:	Projected number of people with Alzheimer disease aged 65 and older, In United States, In million, In 2017	84
Figure 58:	Aggregate cost of care for Alzheimer, By payer, In United States, In 2017	84
Figure 59:	U.S., Population ages 65 and above, Forecast (In Millions)	85
Figure 60:	U.S., GDP (Current USD), 2014-2018 (In USD Trillion)	85

# List of Figures

Figure No.	Figure Title	Page No.
Figure 61:	Canada Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)	87
Figure 62:	Canada Central Nervous System Therapeutic Market Size, By Value, 2019-2024 (USD Billion)	88
Figure 63:	Canada, Population ages 65 and above, 2012-2017 (% of total)	92
Figure 64:	Canada, Expenditure on Health as a share of GDP, 2012-2017 (in %)	93
Figure 65:	Canada, Per Capita Healthcare Expenditure, 2012-2017 (USD)	93
Figure 66:	Incidence, mortality and survival statistics for brain cancer in Canada, In 2017	94
Figure 67:	Prevalence of brain cancer in Canada	94
Figure 68:	Europe Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)	96
Figure 69:	Europe Central Nervous System Therapeutic Market Size, By Value, Forecast, 2019-2024 (USD Billion)	97
Figure 70:	Most frequent neurological diseases reported in primary care, In Europe, 2017	100
Figure 71:	Distribution of Schizophrenia patients worldwide, In 2017, In thousands	100
Figure 72:	Per Capita Health Expenditure, By Select Country, 2017 (USD)	101
Figure 73:	European Union, Population ages 65 and above, 2013-2017 (% of total)	101
Figure 74:	European Country Population Aged 65 and Above, 2012-2017 (% of Total)	102
Figure 75:	GDP, Europe Region, By Select Country, 2017 (In Trillion USD)	102

# List of Figures

Figure No.	Figure Title	Page No.
Figure 76:	Europe Central Nervous System Therapeutic Market: By Type, By Value, 2014-2018 (USD Billion)	104
Figure 77:	Europe Central Nervous System Therapeutic Market: By Type, By Value, 2019E-2024F (USD Billion)	105
Figure 78:	U.K. Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)	107
Figure 79:	U.K. Central Nervous System Therapeutic Market Size, By Value, 2019-2024 (USD Billion)	108
Figure 80:	Most costly neurological disorders in United Kingdom, In 2017	110
Figure 81:	Proportion of people with symptoms of mental disorders in United Kingdom	111
Figure 82:	Proportion of symptoms of mental disorder, By sex, In 2017, In United Kingdom	111
Figure 83:	U.K, Health Expenditure, (% of GDP), 2012-2017 (USD)	112
Figure 84:	U.K, Population Ages 65 and Above (% of total), 2012-2017	112
Figure 85:	UK, Healthcare Infrastructure Related Statistics	112
Figure 86:	U.K, Spending on Healthcare, 2015 & 2040, (USD Per Person)	112
Figure 87:	Germany Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)	114
Figure 88:	Germany Central Nervous System Therapeutic Market Size, By Value, 2019-2024 (USD Billion)	115
Figure 89:	Germany, Population ages 65 and above, 2012-2017 (% total)	117
Figure 90:	Germany, Spending on Healthcare, 2015 & 2040E, (USD Per Person)	117



# List of Figures

Figure No.	Figure Title	Page No.
Figure 91:	Germany, Healthcare Related Statistics, 2017	117
Figure 92:	APAC Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)	119
Figure 93:	APAC Central Nervous System Therapeutic Market Size, By Value, Forecast, 2019-2024 (USD Billion)	120
Figure 94:	GDP Per Capita in APAC, By Select Country, 2016 (In USD)	122
Figure 95:	Population ages 65 and above, By Select Country, 2017 (% of total)	122
Figure 96:	Men Smoking Prevalence in Asia, 2016, (% of Total Population)	122
Figure 97:	Most frequent neurological diseases reported in primary care, In Asia Pacific, 2017	123
Figure 98:	APAC Central Nervous System Therapeutic Market: By Type, By Value, 2014-2018 (USD Billion)	126
Figure 99:	APAC Central Nervous System Therapeutic Market: By Type, By Value, 2019E-2024F (USD Billion)	127
Figure 100:	China Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)	129
Figure 101:	China Central Nervous System Therapeutic Market Size, By Value, 2019-2024 (USD Billion)	130
Figure 102:	China, Smoking Prevalence, Age 15+, % of Total Population, 2012-2016	133
Figure 103:	China, Tobacco Attributable Deaths, 2030	133
Figure 104:	China, Total Population, 2013-2021F (In Billion)	133
Figure 105:	China, GDP Growth Per Year, 2015-2019 (In %)	134

# List of Figures

Figure No.	Figure Title	Page No.
Figure 106:	China, Share of Urban Population, 2012-2017 (In %)	134
Figure 107:	China Healthcare Expenditure Outlook (2017) (%)	134
Figure 108:	China, Population Above 65 (% of Total), 2013-2017	134
Figure 109:	Japan Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)	136
Figure 110:	Japan Central Nervous System Therapeutic Market Size, By Value, 2019-2024 (USD Billion)	137
Figure 111:	Japan, Population ages 65 and above, 2012-2017 (% of total)	140
Figure 112:	Japan, Smoking Prevalence, Age 15+, 2012-2016, (% of Total Prevalence)	140
Figure 113:	Japan Healthcare Expenditure Outlook (%)	140
Figure 114:	India Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)	142
Figure 115:	India Central Nervous System Therapeutic Market Size, By Value, 2019-2024 (USD Billion)	143
Figure 116:	India, Population ages 65 and above, 2013-2017	146
Figure 117:	India, Total Population, 2013-2023F (In Billion)	146
Figure 118:	India, Smoking Prevalence, Age 15+, 2012-2016, (% of Total)	146
Figure 119:	India, Share of Urban Population, 2012-2017 (In %)	147
Figure 120:	India, GDP Growth Per Year, 2015-2019 (In %)	147

# List of Figures

Figure No.	Figure Title	Page No.
Figure 121:	ROW Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)	150
Figure 122:	ROW Central Nervous System Therapeutic Market Size, By Value, Forecast, 2019-2024 (USD Billion)	151
Figure 123:	GDP Per Capita in ROW, By Select Country, 2013 (In USD)	153
Figure 124:	GDP Per Capita in ROW, By Select Country, 2017 (In USD)	153
Figure 125:	Latin America and Caribbean, Population ages 65 and above 2012-2017(% of total)	154
Figure 126:	Middle East and North Africa, Population ages 65 and above (% of total)	154
Figure 127:	Most frequent neurological diseases reported in primary care, In Africa, In 2017	155
Figure 128:	Methods of financing neurological care	155
Figure 129:	ROW Central Nervous System Therapeutic Market: By Type, By Value, 2014-2018 (USD Billion)	157
Figure 130:	ROW Central Nervous System Therapeutic Market: By Type, By Value, 2019E-2024F (USD Billion)	158
Figure 131:	Brazil Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)	160
Figure 132:	Brazil Central Nervous System Therapeutic Market Size, By Value, 2019-2024 (USD Billion)	161
Figure 133:	Brazil, Population ages 65 and above, 2012-17 (% of total)	163
Figure 134:	Brazil, GDP, 2012-2017 (In USD Trillion)	163
Figure 135:	Brazil health expenditure as a share of GDP, 2016	164

# List of Figures

Figure No.	Figure Title	Page No.
Figure 136:	Biogen, Sales Revenue, 2013-2017 (USD Billion)	192
Figure 137:	Biogen, Sales, By Business Segment, FY ended March 2017 (%)	192
Figure 138:	Biogen, Sales, By Geographic region, FY ended March 2017 (%)	192
Figure 139:	Pfizer, Sales Revenue, 2013-2017 (USD million)	194
Figure 140:	Pfizer, Sales, By Business Segment, FY ended March 2017 (In %)	194
Figure 141:	Pfizer, By Geographic Region, FY ended March 2017 (In %)	194
Figure 142:	Teva Pharmaceuticals, Net Sales, 2014-2018 (In Million USD)	196
Figure 143:	Teva Pharmaceuticals, Net Sales, By Business Sector, 2018 (In %)	196
Figure 144:	Teva Pharmaceuticals, Net Sales, By Geographic Region, 2018 (In %)	196
Figure 145:	Novartis, Sales Revenue, 2013-2017 (USD Million)	198
Figure 146:	Novartis, Sales, By Business Segment, FY ended March 2018 (%)	198
Figure 147:	Novartis, By Region, FY ended March 2018 (%)	198
Figure 148:	Johnson & Johnson, Sales Revenue, 2013-2017 (USD Million)	200
Figure 149:	Johnson & Johnson , Sales, By Business Segment, FY ended March 2018 (%)	200
Figure 150:	Johnson & Johnson, By Region, FY ended March 2018 (%)	200

# List of Figures

Figure No.	Figure Title	Page No.
Figure 151:	Shire, Sales Revenue, 2015-2017 (USD Million)	202
Figure 152:	Shire, Sales, By Business Segment, FY ended March 2017 (%)	202
Figure 153:	Shire, By Region, FY ended March 2017 (%)	202
Figure 154:	Merck & Co., Sales Revenue, 2013-2017 (USD Million)	204
Figure 155:	Merck & Co. , Sales, By Business Segment, FY ended March 2017 (%)	204
Figure 156:	Merck & Co., By Region, FY ended March 2017 (%)	204
Figure 157:	AstraZeneca, Sales Revenue, 2013-2017 (USD Million)	206
Figure 158:	AstraZeneca, Sales, By Business Segment, FY ended March 2017 (%)	206
Figure 159:	AstraZeneca, By Region, FY ended March 2017 (%)	206
Figure 160:	Otsuka Pharmaceutical, Sales, By Business Segment, FY ended March 2017 (%)	208

# List of Figures

Figure No.	Figure Title	Page No.
Figure 161:	Otsuka Pharmaceutical, By Region, FY ended March 2017 (%)	208
Figure 162:	Eli Lilly, Sales Revenue, 2013-2017 (USD Million)	210
Figure 163:	Eli Lilly, Sales, By Business Segment, FY ended March 2017 (%)	210
Figure 164:	Eli Lilly, By Region, FY ended March 2017 (%)	210

# List of Figures

Figure No.	Figure Title	Page No.
Table A:	Top 10 diseases causing the most deaths worldwide, In 2017	47
Table B:	Smoking prevalence worldwide, In 2017, By Sex, In %	99
Table C:	Facts about mental health in United Kingdom	110
Table D:	Global Access to Healthcare Index, Ranking of Select Countries in Asia Pacific Region, 2017 (score out of 10)	124
Table E:	Rate of suicides worldwide, In 2017, In number	124
Table F:	National List of Essential medicines in India, By Select Disease, In 2017	148
Table G:	Healthcare spending pattern in Brazil (In USD)	164

# Research Methodology

For our study on Global Central Nervous System Therapeutic Market , we have conducted comprehensive secondary research followed by an extensive primary research. In the process of secondary research, we have scrutinized industry documents, accessed from open sources, premium paid databases (Bloomberg, Thomson Reuters, Factiva) and our internal knowledge base. In the process of primary research, we have interviewed various industry experts across the value chain of healthcare industry.

Market size of the actual period (2014-2018) has been evaluated on the basis of growth trends of the industry in the last five years, and confirming the findings through primary research. Annual reports of the companies were scanned to further validate the market size and to estimate the size of various other end-user sectors. Market sizing and growth in the forecast period (2019-2024) is estimated through product mapping, application in end-user industries, growth of allied sectors and historical growth pattern of the industry. All the relevant data points/ statistics in the forecast period are validated through relevant and reliable primary sources.

**Report Focus:** Global Central Nervous System Therapeutic Market

- By Disease (Cancer, Neurovascular, Degenerative disorder, mental health, trauma, infection)
- By Region (North America, Europe, Asia Pacific and Rest of the World)
- By Country ( U.S., Canada, U.K, Germany, India, China, Japan and Brazil).


**Companies Contacted: Novartis**



# Global Central Nervous System Therapeutic Market

Rise in geriatric population, sedentary lifestyle, obesity rates, stress levels, hyper tension and cardiovascular disease have lead to the growth of global central nervous system therapeutic market in the historic period.

Figure 4: Global Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)



Source: Azoth Analytics Estimates

A Xx

A Xx

A Xx

A Xx

A Xx

# Global Central Nervous System Therapeutic Market

Increase in health awareness, minimization of mental disorder stigma and widening of treatment market through national and international collaboration have contributed to the growth in forecast period.

Figure 5: Global Central Nervous System Therapeutic Market Size, By Value, Forecast, 2019-2024 (USD Billion)




Source: Azoth Analytics Estimates

- A Xx
- A Xx
- A Xx
- A Xx
- A Xx

# Global Central Nervous System Therapeutic Market - By Type


Mental health drugs segment shares the largest portion in the market followed by degenerative disorder in the historic period.

**Figure 22: Global Central Nervous System Therapeutic Market Size, By Type, 2018 (In %)**



Source: Azoth Analytics Estimates


## Key Drivers



# Global Central Nervous System Therapeutic Market - By Type


In the forecast period, brain cancer will be the highest growing segment followed by neurovascular drug market, growing with the CAGR of 9.13% and 8.51% respectively.

**Figure 23: Global Central Nervous System Therapeutic Market Size, By Type, 2024 (In %)**



Source: Azoth Analytics Estimates

## Key Drivers



# Global Brain Cancer Therapeutic Market

**Figure 24: Global Cancer Market, By Value, 2014-2018**

(USD Billion)

**CAGR 2014-2018**


xx%

**Figure 25: Global Cancer Market, By Value, Forecast, 2019-2024(USD Billion)**

(USD Billion)

**CAGR 2019-2024**

xx%



Source: Azoth Analytics Estimates

A Xx

A Xx

A Xx

A Xx

A Xx


# Global Neurovascular Therapeutic Market

**Figure 26: Global Neurovascular Market, By Value, 2014-2018 (USD Billion)**

**CAGR 2014-2018**  
xx%

**Figure 27: Global Neurovascular Market, By Value, Forecast, 2019-2024(USD Billion)**

**CAGR 2019-2024**  
xx%



Source: Azoth Analytics Estimates

- A Xx
- A Xx
- A Xx
- A Xx
- A Xx


# Global Neurodegenerative Disorder Therapeutic Market

**Figure 28: Global Neurodegenerative Market, By Value, 2014-2018 (USD Billion)**

**CAGR 2014-2018**  
xx%

**Figure 29: Global Neurodegenerative Market, By Value, Forecast, 2019-2024(USD Billion)**

**CAGR 2019-2024**  
xx%




Source: Azoth Analytics Estimates

- A Xx
- A Xx
- A Xx
- A Xx
- A Xx

# Global Neurodegenerative Therapeutic Market

Multiple Sclerosis therapeutic market has the maximum share of 74.72% in the historic period from 2014-2018.

**Figure 30: Global Neurodegenerative Therapeutic Market Size, By Value, 2018 (%)**



Source: Azoth Analytics Estimates

## Key Drivers

xx

xx


xx



# Global Neurodegenerative Therapeutic Market

Multiple sclerosis is the most lucrative market in the forecast period, sharing a value of USD 35.48 billion in the forecast period.

**Figure 31: Global Neurodegenerative Therapeutic Market Size, By Value, 2024 (%)**



Source: Azoth Analytics Estimates

## Key Drivers

xx

xx

x


# Global Mental Health Therapeutic Market

**Figure 32: Global Mental Health Market, By Value, 2014-2018 (USD Billion)**

**CAGR 2014-2018**  
xx%

**Figure 33: Global Mental Health Market, By Value, Forecast, 2019-2024(USD Billion)**

**CAGR 2019-2024**  
xx%



Source: Azoth Analytics Estimates

- A Xx
- A Xx
- A Xx
- A Xx
- A Xx


# Global Trauma Therapeutic Market

**Figure 34: Global Trauma Market, By Value, 2014-2018 (USD Billion)**

**CAGR 2014-2018**  
xx%

**Figure 35: Global Trauma Market, By Value, Forecast, 2019-2024(USD Billion)**

**CAGR 2019-2024**  
xx%




Source: Azoth Analytics Estimates

- A Xx
- A Xx
- A Xx
- A Xx
- A Xx

# Global Trauma Therapeutic Market

Post traumatic stress disorder shares the maximum percentage of the trauma therapeutic market in the historic period.

**Figure 36: Global Trauma Therapeutic Market Size, By Value, 2018 (%)**



Source: Azoth Analytics Estimates

## Key Drivers


xx

xx.

# Global Trauma Therapeutic Market

Post traumatic stress disorder is increasing with the CAGR of 5.16% in the forecast period and sharing a value of USD 8.39 billion in 2024.

**Figure 37: Global TraumaTherapeutic Market Size, By Value, 2024 (%)**



Source: Azoth Analytics Estimates

## Key Drivers

xx

x


# Global Brain Infection Therapeutic Market

**Figure 38: Global Brain Infection Market, By Value, 2014-2018 (USD Billion)**

**Figure 39: Global Brain Infection Market, By Value, Forecast, 2019-2024(USD Billion)**

**CAGR 2014-2018**  
xx%

**CAGR 2019-2024**  
xx%




Source: Azoth Analytics Estimates

- A Xx
- A Xx
- A Xx
- A Xx
- A Xx

# Global Central Nervous System Therapeutic Market- Regional Analysis


North America region held the major market share of approximately 43.88%, by value, in the year 2018.

**Figure 41: Global Central Nervous System Therapeutic Market Size, By Region, 2018 (%)**



Source: Azoth Analytics Estimates


## Key Drivers



# Global Central Nervous System Therapeutic Market- Regional Analysis

In the forecast period, North America region is expected to hold its dominant position in the market. However, Asia-Pacific market is anticipated to advance at the highest pace.

**Figure 42: Global Central Nervous System Therapeutic Market Size, By Region, 2024 (%)**



Source: Azoth Analytics Estimates

## Key Drivers

xx

xx


xx



# North America Central Nervous System Therapeutic Market Overview

Heavy investments in medical research and development in addition to high per capita expenditure on healthcare have been the key factors backing the regional central nervous system therapeutic market.

**Figure 43: North America Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)**




Source: Azoth Analytics Estimates

- A Xx
- A Xx
- A Xx
- A Xx
- A Xx

# North America Central Nervous System Therapeutic Market Overview

Growing government initiatives focusing on healthcare policies, rise in sedentary lifestyle and increasing incidence of diabetes and hypertension is likely to drive the market in the forecast period.

**Figure 44: North America Central Nervous System Therapeutic Market Size, By Value, Forecast, 2019-2024 (USD Billion)**




Source: Azoth Analytics Estimates

# North America Central Nervous System Therapeutic Market, By Type

Figure 50: North America Central Nervous System Therapeutic Market: By Type, By Value, 2014-2018 (USD Billion)

**CAGR 2014-2018**  
 Cancer: xx%  
 Neurovascular: xx%  
 Neurodegenerative disorder: xx%  
 Mental Health: xx%  
 Trauma: xx%  
 Infection: xx%



	2014	2015	2016	2017	2018
Cancer	xx	xx	xx	xx	xx
Neurovascular	xx	xx	xx	xx	xx
Neurodegenerative disorder	xx	xx	xx	xx	xx
Mental Health	xx	xx	xx	xx	xx
Trauma	xx	xx	xx	xx	xx
Brain Infection	xx	xx	xx	xx	xx


A Xx

A Xx

# North America Central Nervous System Therapeutic Market, By Type

Figure 51: North America Central Nervous System Therapeutic Market: By Type, By Value, 2019E-2024F (USD Billion)

**CAGR 2019-2024**  
 Cancer: xx%  
 Neurovascular: xx%  
 Neurodegenerative disorder: xx%  
 Mental Health: xx%  
 Trauma: xx%  
 Infection: xx%




	2019	2020	2021	2022	2023	2024
Cancer	xx	xx	xx	xx	xx	xx
Neurovascular	xx	xx	xx	xx	xx	xx
Neurodegenerative disorder	xx	xx	xx	xx	xx	xx
Mental Health	xx	xx	xx	xx	xx	xx
Trauma	xx	xx	xx	xx	xx	xx
Brain Infection	xx	xx	xx	xx	xx	xx

A Xx

A Xx

# U.S. Central Nervous System Therapeutic Market, By Value

Figure 52: U.S. Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)




Source: Azoth Analytics Estimates

- A Xx
- A Xx
- A Xx
- A Xx
- A Xx

# U.S. Central Nervous System Therapeutic Market, By Value

Figure 53: U.S. Central Nervous System Therapeutic Market Size, By Value, 2019-2024 (USD Billion)



Source: Azoth Analytics Estimates

- A Xx
- A Xx
- A Xx
- A Xx
- A Xx

## About Azoth Analytics Pvt Ltd.

Azoth Analytics is a business research and analytics firm that creates in-depth research reports and provides customized research solutions and consultancy services. Verticals in which Azoth Analytics specializes include healthcare and pharmaceutical, oil and gas, retail, chemicals, automotive, FMCG, food & beverages and technology. Azoth creates comprehensive and in-depth research reports by recording, interpreting and analyzing information. Strategic market sizing and data dredging techniques include secondary research, and primary research (interviews with management personnel and industry experts).

## Related Reports:

**Disclaimer:** *Azoth Analytics report information is based mainly on interviews and therefore, is subject to fluctuation. Azoth Analytics therefore, takes no responsibility for any incorrect information supplied to us by industry experts, manufacturers or users. Azoth does not warranty the completeness of the information and data. Also, analysis provided in the report are meant for customers' internal use only and not for general publication or disclosure to third parties.*